The FDA adverse-event record for snake

Snake Adverse Event Insights

The FDA Center for Veterinary Medicine database holds 12 adverse event reports for Snake, distributed across 4 distinct breeds currently tracked in the system. Of those reports, 4 involved a death outcome, producing a 33.3% case-fatality rate among reported events, which reflects reporting severity bias rather than true population mortality. These figures are aggregated directly from openFDA's Animal & Veterinary Adverse Events endpoint and update as new voluntary submissions flow through pet owners, veterinarians, and drug manufacturers.

The most frequently reported clinical signs for Snake are Death (4 reports), Lethargy (see also Central nervous system depression in 'Neurological') (2 reports), Limpness (2 reports), Bradypnoea (2 reports), with Death leading the reaction traffic at 4 submissions. On the product side, Fenbendazol Suspension is the single most-referenced drug with 4 reports, followed by Dexmedetomidine Hydrochloride (3), Alfaxalone (2), Enrofloxacin (1). This combination surfaces which therapeutic classes generate the most adverse event chatter for this species, a useful starting point when comparing Snake reporting patterns against other companion animals in the dataset.

Of the 12 Snake reports with a coded outcome, Recovered/Normal accounts for the largest share at 58.3%. Annual submission volume spans 2,011 to 2,022 reports across the 6 years on file, a range that reflects evolving owner awareness, veterinary reporting habits, and new product approvals rather than stable underlying incidence. The breed-level table below breaks these patterns down further, showing how the 4 tracked snake breeds compare on volume, deaths, and average age at report. As with all FDA adverse event data, correlation is the ceiling, causation requires clinical investigation beyond what these aggregates can provide.